Preferences of people living with HIV for injectable and oral antiretroviral treatment in the Netherlands: a discrete choice experiment

References

• Aschenbrenner, D. S. (2021). First extended-release injectable drug therapy for HIV. American Journal of Nursing, 121(5), 24–25. https://doi.org/10.1097/01.Naj.0000751096.82989.00
   Web of Science ®Google Scholar
• Beckham, S. W., Crossnohere, N. L., Gross, M., & Bridges, J. F. P. (2021). Eliciting preferences for HIV prevention technologies: A systematic review. The Patient, 14(2), 151–174. https://doi.org/10.1007/s40271-020-00486-9
   PubMedGoogle Scholar
• Bridges, J. F., Hauber, A. B., Marshall, D., Lloyd, A., Prosser, L. A., Regier, D. A., Johnson, F. R., & Mauskopf, J. (2011). Conjoint analysis applications in health–a checklist: A report of the ISPOR good research practices for conjoint analysis task force. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 14(4), 403–413. https://doi.org/10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Clark, M. D., Determann, D., Petrou, S., Moro, D., & de Bekker-Grob, E. W. (2014). Discrete choice experiments in health economics: A review of the literature. Pharmacoeconomics, 32(9), 883–902. https://doi.org/10.1007/s40273-014-0170-x
   PubMed Web of Science ®Google Scholar
• Flexner, C., Owen, A., Siccardi, M., & Swindells, S. (2021). Long-acting drugs and formulations for the treatment and prevention of HIV infection. International Journal of Antimicrobial Agents, 57(1), Article 106220. https://doi.org/10.1016/j.ijantimicag.2020.106220
   PubMed Web of Science ®Google Scholar
• Hauber, A. B., González, J. M., Groothuis-Oudshoorn, C. G., Prior, T., Marshall, D. A., Cunningham, C., IJzerman, M. J., & Bridges, J. F. P. (2016). Statistical methods for the analysis of discrete choice experiments: A report of the ISPOR conjoint analysis good research practices task force. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 19(4), 300–315. https://doi.org/10.1016/j.jval.2016.04.004
   PubMed Web of Science ®Google Scholar
• Humphrey, J. M., Naanyu, V., MacDonald, K. R., Wools-Kaloustian, K., & Zimet, G. D. (2019). Stated-preference research in HIV: A scoping review. PLoS One, 14(10), Article e0224566. https://doi.org/10.1371/journal.pone.0224566
   Web of Science ®Google Scholar
• Iacob, S. A., Iacob, D. G., & Jugulete, G. (2017). Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Frontiers in Pharmacology, 8, Article 831. https://doi.org/10.3389/fphar.2017.00831
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV/AIDS (UNAIDS). (2014). 90-90-90: An ambitious treatment target to help end the AIDS epidemic. https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf
   Google Scholar
• Katz, I. T., Ryu, A. E., Onuegbu, A. G., Psaros, C., Weiser, S. D., Bangsberg, D. R., & Tsai, A. C. (2013). Impact of HIV-related stigma on treatment adherence: Systematic review and meta-synthesis. Journal of the International AIDS Society, 16(3 Suppl 2), Article 18640. https://doi.org/10.7448/IAS.16.3.18640
   PubMedGoogle Scholar
• Kruijshaar, M. E., Essink-Bot, M.-L., Donkers, B., Looman, C. W. N., Siersema, P. D., & Steyerberg, E. W. (2009). A labelled discrete choice experiment adds realism to the choices presented: Preferences for surveillance tests for barrett esophagus. BMC Medical Research Methodology, 9(1), Article 31. https://doi.org/10.1186/1471-2288-9-31
   PubMedGoogle Scholar
• Markham, A. (2020). Cabotegravir plus rilpivirine: First approval. Drugs, 80(9), 915–922. https://doi.org/10.1007/s40265-020-01326-8
   PubMed Web of Science ®Google Scholar
• Marsh, K., van Til, J. A., Molsen-David, E., Juhnke, C., Hawken, N., Oehrlein, E. M., Choi, Y. C., Duenas, A., Greiner, W., Haas, K., Hiligsmann, M., Hockley, K. S., Ivlev, I., Liu, F., Ostermann, J., Poder, T., Poon, J. L., & Muehlbacher, A. (2020). Health preference research in Europe: A review of Its Use in marketing authorization, reimbursement, and pricing decisions-report of the ISPOR stated preference research special interest group. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 23(7), 831–841. https://doi.org/10.1016/j.jval.2019.11.009
   PubMed Web of Science ®Google Scholar
• Mills, E. J., Nachega, J. B., Bangsberg, D. R., Singh, S., Rachlis, B., Wu, P., Wilson, K., Buchan, I., Gill, C. J., & Cooper, C. (2006). Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine, 3(11), Article e438. https://doi.org/10.1371/journal.pmed.0030438
   Web of Science ®Google Scholar
• Murray, M., Antela, A., Mills, A., Huang, J., Jäger, H., Bernal, E., Lombaard, J., Katner, H., Walmsley, S., Khuong-Josses, M. A., Hudson, K., Dorey, D., Griffith, S., Spreen, W., Vanveggel, S., Shaefer, M., Margolis, D., & Chounta, V. (2020). Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS and Behavior, 24(12), 3533–3544. https://doi.org/10.1007/s10461-020-02929-8
   PubMed Web of Science ®Google Scholar
• Nachega, J. B., Parienti, J. J., Uthman, O. A., Gross, R., Dowdy, D. W., Sax, P. E., Gallant, J. E., Mugavero, M. J., Mills, E. J., & Giordano, T. P. (2014). Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 58(9), 1297–1307. https://doi.org/10.1093/cid/ciu046
   PubMed Web of Science ®Google Scholar
• Orkin, C., Arasteh, K., Górgolas Hernández-Mora, M., Pokrovsky, V., Overton, E. T., Girard, P. M., Oka, S., Walmsley, S., Bettacchi, C., Brinson, C., Philibert, P., Lombaard, J., St Clair, M., Crauwels, H., Ford, S. L., Patel, P., Chounta, V., D'Amico, R., Vanveggel, S., … Spreen, W. R. (2020). Long-Acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. New England Journal of Medicine, 382(12), 1124–1135. https://doi.org/10.1056/NEJMoa1909512
   PubMed Web of Science ®Google Scholar
• Overton, E. T., Richmond, G., Rizzardini, G., Jaeger, H., Orrell, C., Nagimova, F., Bredeek, F., García Deltoro, M., Swindells, S., Andrade-Villanueva, J. F., Wong, A., Khuong-Josses, M. A., Van Solingen-Ristea, R., van Eygen, V., Crauwels, H., Ford, S., Talarico, C., Benn, P., Wang, Y., … Spreen, W. (2020). Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study. The Lancet, 396(10267), 1994–2005. https://doi.org/10.1016/S0140-6736(20)32666-0
   PubMed Web of Science ®Google Scholar
• Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., & Singh, N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21–30. https://doi.org/10.7326/0003-4819-133-1-200007040-00004
   PubMed Web of Science ®Google Scholar
• Reed Johnson, F., Lancsar, E., Marshall, D., Kilambi, V., Mühlbacher, A., Regier, D. A., Regier, D., Bresnahan, B. W., Kanninen, B., & Bridges, J. F. (2013). Constructing experimental designs for discrete-choice experiments: Report of the ISPOR conjoint analysis experimental design good research practices task force. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(1), 3–13. https://doi.org/10.1016/j.jval.2012.08.2223
   PubMed Web of Science ®Google Scholar
• Simoni, J. M., Beima-Sofie, K., Mohamed, Z. H., Christodoulou, J., Tapia, K., Graham, S. M., Ho, R., & Collier, A. C. (2019). Long-acting injectable antiretroviral treatment acceptability and preferences: A qualitative study Among US providers, adults living with HIV, and parents of youth living with HIV. AIDS Patient Care and STDs, 33(3), 104–111. https://doi.org/10.1089/apc.2018.0198
   PubMed Web of Science ®Google Scholar
• Simoni, J. M., Tapia, K., Lee, S. J., Graham, S. M., Beima-Sofie, K., Mohamed, Z. H., Christodoulou, J., Ho, R., & Collier, A. C. (2020). A conjoint analysis of the acceptability of targeted long-acting injectable antiretroviral therapy among persons living with HIV in the U.S. AIDS and Behavior, 24(4), 1226–1236. https://doi.org/10.1007/s10461-019-02701-7
   PubMed Web of Science ®Google Scholar
• Swindells, S., Andrade-Villanueva, J. F., Richmond, G. J., Rizzardini, G., Baumgarten, A., Masiá, M., Latiff, G., Pokrovsky, V., Bredeek, F., Smith, G., Cahn, P., Kim, Y. S., Ford, S. L., Talarico, C. L., Patel, P., Chounta, V., Crauwels, H., Parys, W., Vanveggel, S., … Spreen, W. R. (2020). Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. New England Journal of Medicine, 382(12), 1112–1123. https://doi.org/10.1056/NEJMoa1904398
   PubMed Web of Science ®Google Scholar
• van Sighem, A. I., Wit, F. W. N. M., Boyd, A., Smit, C., Matser, A., & Reiss, P. (2019). Monitoring Report 2019. Human Immunodeficiency Virus (HIV) Infection in the Netherlands. Stichting HIV Monitoring. https://www.hiv-monitoring.nl/application/files/4115/7616/1682/HIV_Monitoring_Report_2019_update_dec_2019.pdf
   Google Scholar
• Zhou, M., Thayer, W. M., & Bridges, J. F. P. (2018). Using latent class analysis to model preference heterogeneity in health: A systematic review. Pharmacoeconomics, 36(2), 175–187. https://doi.org/10.1007/s40273-017-0575-4
   PubMed Web of Science ®Google Scholar